Method For Inhibiting Coronavirus Infection And Replication

Abstract

Disclosed herein is a method for inhibiting coronavirus infection, including administering to a subject in need thereof an effective amount of pioglitazone or a pharmaceutically acceptable salt thereof. Also disclosed is a method for inhibiting coronavirus replication, including contacting a coronavirus with pioglitazone or a pharmaceutically acceptable salt thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims priority of U.S. Provisional Application No. 63/037,889, filed on Jun. 11, 2020.

FIELD

[0002] The present disclosure relates to a method for inhibiting coronavirus infection and replication using pioglitazone.

BACKGROUND

[0003] Coronaviruses are a group of related RNA viruses belonging to the Coronaviridae family which infect mammals and birds. These viruses have viral envelope with a positive-sense, single-stranded RNA genome, and are characterized by club-shaped spikes that project from their surface, which create an image reminiscent of solar corona in electron microscope, from which their name derives.

[0004] To date, there are seven known coronaviruses which infect humans, including human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), human coronavirus 229E (HCoV-229E), and human coronavirus NL63 (HCoV-NL63) which produce generally mild symptoms of common cold, and Middle East respiratory syndrome-related coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which produce symptoms that are potentially severe.

[0005] Notably, SARS-CoV-2 is identified as the viral strain that causes the current outbreak of coronavirus disease 2019 (COVID-19), the rapid spread of which was declared as a global pandemic known as COVID-19 pandemic. Till date, more than 20 million confirmed cases of COVID-19 had been reported worldwide, with a fatality rate of approximately 3.5%. Transmission of SARS-CoV-2 between humans primarily occurs during close contact, usually via small droplets produced by coughing, sneezing and talking. Symptoms of COVID-19 may be relatively non-specific, including fever, cough, fatigue, phlegm production, loss of sense of smell, shortness of breath, muscle and joint pain, headache, and chills, among others. Among COVID-19 patients who develop symptoms, approximately one in five may become seriously ill and have difficulty in breathing. Further development of COVID-19 may lead to complications, including pneumonia, acute respiratory distress syndrome, sepsis, septic shock, and kidney failure. Due to travel restrictions, lockdowns, workplace hazard controls, and facility closures imposed by governmental authorities worldwide, COVID-19 pandemic has caused global social and economic disruption, including the largest global recession since the Great Depression. With no known vaccine or specific antiviral treatment currently available, the need to find and/or develop drugs effective against coronavirus, particularly SARS-CoV-2, has become pressing.

[0006] Drug repositioning (also known as drug repurposing) is the investigation of existing drugs for new therapeutic purposes. This research direction, along with development of COVID-19 vaccines and convalescent plasma transfusion, is being actively pursued to develop safe and effective COVID-19 treatments. In fact, several existing antiviral medications, previously developed or used in treatments for SARS, MERS, HIV/AIDS, and malaria, are being investigated as COVID-19 treatment candidates. A few of these medications, such as chloroquine and hydroxychloroquine, dexamethasone, favipiravir, lopinavir/ritonavir, remdesivir, etc., have advanced into clinical trials. However, based on published randomized controlled trials, none of these medications has yet been shown to be clearly effective in reducing mortality of COVID-19 patients. Therefore, there is still an urgent need to find other classes of drugs which are effective against SARS-CoV-2.

[0007] Pioglitazone is a drug classified as a thiazolidinedione compound which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. The drug was developed by Takeda Pharmaceutical Company and is being sold under trade names Actos.RTM., Glustin@, Glizone.RTM., among others. Pioglitazone works by modulating the transcription of genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissues, and the liver, thereby reducing insulin resistance in the liver and peripheral tissues, decreasing gluconeogenesis in the liver, and reducing the amount of glucose and glycated hemoglobin in the bloodstream. However, it remains unknown whether pioglitazone has an antiviral effect, particularly an inhibitory effect on coronavirus infection.

SUMMARY

[0008] Therefore, an object of the present disclosure is to provide a method for inhibiting coronavirus infection which can alleviate at least one of the drawbacks of the prior art.

[0009] According to the present disclosure, the method for inhibiting coronavirus infection includes administering to a subject in need thereof an effective amount of pioglitazone or a pharmaceutically acceptable salt thereof.

[0010] Another object of the present disclosure is to provide a method for inhibiting coronavirus replication which can alleviate at least one of the drawbacks of the prior art.

[0011] According to the present disclosure, the method for inhibiting coronavirus replication includes contacting a coronavirus with pioglitazone or a pharmaceutically acceptable salt thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Other features and advantages of the present disclosure will become apparent in the following detailed description of the embodiments with reference to the accompanying drawings, of which:

[0013] FIG. 1 shows cell viability of mock-infected and HCoV-229E-infected LLC-MK2 cells pretreated with different concentrations of pioglitazone at 7 days post-infection (d.p.i.), in which the symbols "*", "**", "***" and "****" respectively represent p<0.05, p<0.01, p<0.005 and p<0.001;

[0014] FIG. 2 shows virus titers of HCoV-229E in a control group and infected LLC-MK2 cells pretreated with 20 .mu.M pioglitazone (upper panel) and virus titers of HCoV-OC43 in a control group and infected Vero E6 cells pretreated with 20 .mu.M pioglitazone (lower panel) at 1, 2, and 3 d.p.i., in which the symbols "*", "**" and "***" respectively represent p<0.05, p<0.01 and p<0.005;

[0015] FIG. 3 shows RNA copy numbers of E gene (upper panel) and RdRp gene (lower panel) of SARS-CoV-2 in a control group and infected LLC-MK2 cells pretreated with 20 .mu.M pioglitazone at 1, 2, 3, and 4 d.p.i., in which the symbols "*" and "****" respectively represent p<0.05 and p<0.001;

[0016] FIG. 4 shows fluorescence microscopy images of expression of spike (S) and nucleocapside (NP) proteins of SARS-CoV-2 in a control group, mock-infected LLC-MK2 cells and virus-infected LLC-MK2 cells pretreated with pioglitazone at 4 d.p.i., in which the nucleus of LLC-MK2 cells was stained with DAPI and the scale bar of each images is 50 .mu.m; and

[0017] FIG. 5 shows distribution and size of viral plaques of SARS-CoV-2 in a control group and infected Vero E6 cells treated with pioglitazone at 3 d.p.i.

DETAILED DESCRIPTION

[0018] It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Taiwan or any other country.

[0019] For the purpose of this specification, it will be clearly understood that the word "comprising" means "including but not limited to", and that the word "comprises" has a corresponding meaning.

[0020] Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of this disclosure. Indeed, this disclosure is in no way limited to the methods and materials described.

[0021] In the development of drugs that can be used to treat coronavirus infection, the applicants unexpectedly found that pioglitazone can significantly reduce the viral titer and inhibit viral replication of coronavirus in infected host cells, and hence is expected to be effective against coronavirus infection.

[0022] Therefore, the present disclosure is directed to use of pioglitazone or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for inhibiting coronavirus infection and/or coronavirus replication.

[0023] The present disclosure also provides a method for inhibiting coronavirus infection, including administering to a subject in need thereof an effective amount of pioglitazone or the pharmaceutically acceptable salt thereof.

[0024] The present disclosure also provides a method for inhibiting coronavirus replication, including contacting a coronavirus with pioglitazone or the pharmaceutically acceptable salt thereof.

[0025] As used herein, the term "administration" or "administering" means introducing, providing or delivering a pre-determined active ingredient to a subject by any suitable routes to perform its intended function.

[0026] As used herein, the term "subject" refers to any animal of interest, such as humans, monkeys, cows, sheep, horses, pigs, goats, dogs, cats, mice, and rats. In certain embodiments, the subject is a human.

[0027] As used herein, the term "pharmaceutically acceptable salt" refers to any salt, which, upon administration to the subject is capable of providing (directly or indirectly) a compound as described herein (i.e., pioglitazone) without undue toxicity, irritation, allergic response and the like. In particular, "pharmaceutically acceptable salt" may encompass those approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The preparation of salts can be carried out by methods known in the art.

[0028] For instance, the pharmaceutically acceptable salts of pioglitazone may be acid addition salts, base addition salts or metallic salts, and they can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent or in a mixture thereof. Examples of the acid addition salts may include mineral acid addition salts such as, for example, hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, and phosphate; and organic acid addition salts such as, for example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate, p-toluenesulphonate, 2-naphtalenesulphonate, and 1,2-ethanedisulphonate. Examples of the alkali addition salts may include inorganic salts such as, for example, ammonium; and organic alkali salts such as, for example, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine, choline, glucamine, and basic aminoacids salts. Examples of the metallic salts may include, for example, sodium, potassium, calcium, magnesium, aluminium, and lithium salts.

[0029] According to this disclosure, the coronavirus infection is caused by a coronavirus selected from the group consisting of a member of Alphacoronavirus genus, a member of Betacorovirus genus, a member of Gammacoronavirus genus, a member of Deltacoronavirus genus, and combinations thereof.

[0030] Examples of the member of Alphacoronavirus genus may include, but are not limited to, Colavirus, Decacovirus, Duvinacovirus, Luchacovirus, Minacovirus, Minunacovirus, Myotacovirus, Nyctacovirus, Pedacovirus, Rhinacovirus, Setracovirus, Soracovirus, Sunacovirus, Tegacovirus, and combinations thereof. For example, the member of Alphacoronavirus genus may be bat coronavirus CDPHE 15, bat coronavirus HKU10, Rhinolopus ferrumequinum alphacoronavirus HuB-2013, human coronavirus 229E (HCoV-229E), Lucheng Rn rat coronavirus, mink coronavirus 1, Miniopterus bat coronavirus 1, Miniopterus bat coronavirus HKU8, Myotis ricketti alphacoronavirus Sax-2011, Nyctalus velutinus alphacoronavirus SC-2013, Pipistrellus kuhlii coronavirus 3398, porcine epidemic diarrhea virus, Scotophilus bat coronavirus 512, Rhinolophus bat coronavirus HKU2, human coronavirus NL63, NL63-related bat coronavirus strain BtKYNL63-9b, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, or Alphacoronavirus 1.

[0031] Examples of the member of Betacoronavirus genus may include, but are not limited to, Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, and combinations thereof. For example, the member of Betacoronavirus genus may be bovine coronavirus, human coronavirus OC43 (HCoV-OC43), China rattus coronavirus HKU24, human coronavirus HKU1, murine coronavirus, Myodes coronavirus 2JL14, bat Hp-betacoronavirus Zhejiang 2013, Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus, Pipistrellus bat coronavirus HKU5, Tylonycteris bat coronavirus HKU4, Eidolon bat coronavirus C704, Rousettus bat coronavirus GCCDC1, Rousettus bat coronavirus HKU9, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or bat SARS-like coronavirus WIV1.

[0032] Examples of the member of Gammacoronavirus genus may include, but are not limited to, Brangacovirus, Cegacovirus, Igacovirus, and combinations thereof. For example, the member of Gammacoronavirus genus may be goose coronavirus CB17, Beluga whale coronavirus SW1, avian coronavirus, avian coronavirus 9203, or duck coronavirus 2714.

[0033] Examples of the member of Deltacoronavirus genus may include, but are not limited to, Andecovirus, Buldecovirus, Herdecovirus, and combinations thereof. For example, the member of Deltacoronavirus genus may be Wigeon coronavirus HKU20, Bulbul coronavirus HKU11, Common moorhen coronavirus HKU21, Coronavirus HKU15, Munia coronavirus HKU13, White-eye coronavirus HKU16, or Night heron coronavirus HKU19.

[0034] In an exemplary embodiment, the coronavirus is HCoV-229E. In another exemplary embodiment, the coronavirus is HCoV-OC43. In yet another exemplary embodiment, the coronavirus is SARS-CoV-2.

[0035] According to this disclosure, pioglitazone or the pharmaceutically acceptable salt thereof may be prepared into a pharmaceutical composition in a dosage form suitable for, e.g., oral administration, using technology well known to those skilled in the art. Examples of the dosage form for oral administration may include, but are not limited to, sterile powder, tablets, troches, lozenges, capsules, dispersible powder, granule, solutions, suspensions, emulsions, syrup, elixirs, slurry, and the like.

[0036] According to this disclosure, the pharmaceutical composition may further include a pharmaceutically acceptable carrier that is widely employed in the art of drug-manufacturing. Examples of the pharmaceutically acceptable carrier may include, but are not limited to, solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrating agents, dispersing agents, binding agents, excipients, stabilizing agents, chelating agents, diluents, gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, liposomes, and the like. The choice and amount of the pharmaceutically acceptable carrier are within the expertise of those skilled in the art.

[0037] The dosage and the frequency of administration of pioglitazone or the pharmaceutically acceptable salt thereof may vary depending on the following factors: the severity of the illness/viral infection to be treated and the weight, age, physical condition and response of the subject to be treated.

[0038] The present disclosure will be further described by way of the following examples. However, it should be understood that the following examples are intended solely for the purpose of illustration and should not be construed as limiting the present disclosure in practice.

Examples

General Experimental Materials:

[0039] 1. Pioglitazone was purchased from Sigma Aldrich. 2. Primers used in the following examples were synthesized by Taqkey Science Co., Ltd., Taiwan. 3. Cell cultures

[0040] Rhesus monkey kidney epithelial (LLC-MK2) cells (ATCC CCL-7) and African green monkey kidney (Vero-E6) cells (ATCC CRL-1586) used in the following experiments were purchased from ATCC (American Type Culture Collection, Manassas, Va., USA). Human hepatocellular carcinoma (Huh-7) cells (Ser. No. 01/042,712) was purchased from Sigma Aldrich. The cells of the respective type were incubated in a cell culture dish, where LLC-MK2 cells and Vero-E6 cells were incubated in minimum essential medium (MEM; Gibco, Grand Island, N.Y.) and Huh-7 cells were incubated in Dulbecco's Modified Eagle's Medium (DMEM; Gibco), each supplemented with 10% fetal bovine serum (FBS; Gibco), followed by cultivation in an incubator with culture conditions set at 37.degree. C. or 33.degree. C. and 5% CO.sub.2. Medium change was performed every 3 days. Cell passage was performed when the cultured cells reached 90% of confluence.

4. Virus strains

[0041] Human coronavirus 229E (HCoV-229E) (ATCC VR-740) and human coronavirus OC43 (HCoV-OC43) (ATCC VR-1558) used in the following experiments were purchased from ATCC. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was isolated from nasopharyngeal swab of a patient diagnosed with coronavirus disease 2019 (COVID-19) who was followed and treated at Chang-Gung Memorial Hospital, Linkou, Taiwan (CGMH-CGU-01).

General Experimental Procedures:

1. Virus Infection

[0042] When the cultured cells reached 80% to 90% of confluence, infection by viruses, such as HCoV-229E, HCoV-OC43 or SARS-CoV-2, at a given multiplicity of infection (m.o.i.), was performed in serum-free MEM. The viruses were allowed to adsorb at 37.degree. C. (HCoV-229E and SARS-CoV-2) or 33.degree. C. (HCoV-OC43) for 1 hour, after which the infected cells were washed with phosphate-buffered saline (PBS) and incubated at 37.degree. C. or 33.degree. C. in MEM containing 2% FBS.

2. Statistical Analysis

[0043] The experimental data are expressed as mean.+-.standard error of the mean (SEM), and were analyzed by Student's two-tailed unpaired t-test using GraphPad Prism 6 software (GraphPad Software, Inc., California, USA), where p-values<0.05 were considered to be statistically significant.

Example 1. Evaluation of the Effect of Pioglitazone on Cell Viability of HCoV-229E-Infected Cells

Experimental Procedures:

[0044] LLC-MK2 cells were seeded in a 96-well plate at 2000 cells per well. After 24 hours, the cells were pretreated with pioglitazone, at concentrations of 0, 5, 10, 20, 40, 60, 80, 100, and 120 .mu.M, respectively, for 1 hour. Subsequently, the pretreated cells were infected with HCoV-229E at m.o.i. of 0.01 for 7 days according to the procedures as described in the preceding section, entitled "1. Virus infection," of the General Experimental Procedures. Mock-infected cells served as a control group. HCoV-229E-infected cells and mock-infected cells were subjected to cell viability determination using CellTiter96 Aqueous One Solution Cell Proliferation Assay (Promega).

Results:

[0045] FIG. 1 illustrates cell viability of HCoV-229E-infected and mock-infected LLC-MK2 cells that were pretreated with increasing concentrations of pioglitazone. As shown in FIG. 1, pioglitazone is capable of increasing cell viability of HCoV-229E-infected LLC-MK2 cells as compared to the control group, indicating that infection of coronavirus, such as HCoV-229E, can be inhibited by pioglitazone.

Example 2. Evaluation of the Effect of Pioglitazone on Viral Yield in HCoV-229E-Infected and HCoV-OC43-Infected Cells

Experimental Procedures:

[0046] LLC-MK2 cells and Vero E6 cells were pretreated with 20 .mu.M of rosiglitazone for 1 hour, and then were respectively infected with HCoV-229E and HCoV-OC43 at m.o.i. of 0.01 according to the procedures as described in the preceding section, entitled "1. Virus infection," of the General Experimental Procedures.

[0047] The HCoV-229E in the infected LLC-MK2 cells and the HCoV-OC43 in the infected Vero E6 cells were harvested at 1, 2, and 3 days post-infection (d.p.i.) for determination of virus titers.

[0048] Each of HCoV-229E and HCoV-OC43 was subjected to a ten-fold dilution using serum-free DMEM or MEM, so as to obtain a diluted viral solution having a dilution factor of 10 for use in the following viral plaque assay.

[0049] Huh-7 cells and Vero E6 cells were seeded at 8.times.10, and 5.times.10.sup.5 cells per well into respective wells of 6-well plates containing 10% FBS DMEM or MEM, and were cultured in an incubator (37.degree. C. and 5% CO.sub.2) for 24 hours. Thereafter, the Huh-7 cells and Vero E6 cells were infected with the diluted solutions (500 .mu.L) of HCoV-229E and HCoV-OC43, respectively, according to the procedures as described in the preceding section, entitled "1. Virus infection," of the General Experimental Procedures. After that, the HCoV-229E-infected Huh-7 cells and the HCoV-OC43-infected Vero E6 cells were washed with PBS, and then 3 mL of an agarose overlay medium (0.3% agarose in DMEM or MEM containing 2% FBS) was added to each well. After the agarose overlay medium had solidified, the plates were placed in an incubator set at 37.degree. C. for the HCoV-229E-infected Huh-7 cells or at 33.degree. C. for the HCoV-OC43-infected Vero E6 cells.

[0050] The cells in each well were fixed with 2 mL of a 10% formaldehyde solution at room temperature for 2 hours. Next, the agarose overlay in each well was removed, and then the fixed cells in each well were stained with 0.5% crystal violet (Manufacturer: Sigma Aldrich) for 2 min. After rinsing the stained cells with water, the viral plaques in each well were counted. The viral titer (plaque forming units (P.F.U.)/mL) was determined by the following formula (1):

A=B/(C.times.0.5) (1)

wherein: A=viral titer [0051] B=the viral plaques counted [0052] C=the dilution factor of the virus

[0053] In comparison, Huh-7 cells and Vero E6 cells pretreated with dimethyl sulfoxide (DMSO) (serving as control groups) were subjected to the same analysis.

Results:

[0054] FIG. 2 shows virus titers (expressed as log P.F.U./mL) of the HCoV-229E and HCoV-OC43 respectively in the infected Huh-7 cells pretreated with pioglitazone (upper panel) and the infected Vero E6 cells pretreated with pioglitazone (lower panel) at 1, 2, and 3 d.p.i. As shown in FIG. 2, as compared to the control groups, viral yields of the HCoV-229E and HCoV-OC43 in the infected cells pretreated with pioglitazone are significantly lower, indicating that pioglitazone is effective in reducing viral replication in host cells infected with coronavirus.

Example 3. Evaluation of the Effects of Pioglitazone on Viral Gene Expression and Viral Yields in SARS-CoV-2-Infected Cells

A. Quantitative Determination of Viral Gene Expression

[0055] LLC-MK2 cells were pretreated with 20 .mu.M of pioglitazone for 1 hour, and then were infected with SARS-CoV-2 at m.o.i. of 0.01 according to the procedures as described in the preceding section, entitled "1. Virus infection," of the General Experimental Procedures.

[0056] At 1, 2, 3 and 4 d.p.i., viral RNA was extracted using LabTurbo Viral Mini Kit with LabTurbo 48 Compact System (Taigen Bioscience Corporation), and was used as a template for synthesizing cDNA by reverse transcription polymerase chain reaction (RT-PCR) using MMLV Reverse Transcription kit (Protech Technology). Thereafter, the thus obtained cDNA, serving as a DNA template, was subjected to quantitative PCR (qPCR), which was performed on a LightCycler@480 System (Roche Life Science) using the PCR reaction mixture and the reaction conditions shown in Table 1, so as to determine the RNA copy number of viral target genes, including Envelope (E) and RNA-dependent RNA polymerase (RdRp) genes of SARS-CoV-2. The SARS-CoV-2-E gene-specific primers and probe and the SARS-CoV-2-RdRp gene-specific primers and probe listed in Table 2 were designed following recommendations by the Taiwan Center for Disease Control (CDC).

[0057] In comparison, LLC-MK2 cells pretreated with DMSO (serving as control group) were subjected to the same analysis.

TABLE-US-00001 TABLE 1 Volume Contents (&muL) cDNA 1 E gene-specific Forward primer (10 .mu.M) 0.5 pramers and probe Reverse primer (10 .mu.M) 0.5 5'FAM probe (10 .mu.M) 0.5 RdRp gene-specific Forward primer (10 .mu.M) 0.5 primers and probe Reverse primer (10 .mu.M) 0.5 5'FAM probe (5 .mu.M) 0.5 2 .times. qPCRBIO Probe Blue Mix Lo-ROX 5 (PCR Biosystems) DEPC-treated d.sub.2H.sub.2O 2.5 Operation conditions: Denaturation at 95.degree. C. for 5 min, followed by 50 cycles of the following reactions: denaturation at 95.degree. C. for 5 sec, and primer annealing and extension at 72.degree. C. for 10 sec.

TABLE-US-00002 TABLE 2 Viral Nucleotide sequence SEQ ID gene Primer/Probe (5'.fwdarw.3') NO. E gene Forward primer acaggtacgttaatagtta 1 atagcgt Reverse primer atattgcagcagtacgcac 2 aca 5' FAM probe FAM-acactagccatcctt 3 actgcgcttcg-BBQ RdRp Forward primer gtgaratggtcatgtgtgg 4 gene cgg Reverse primer caratgttaaasacactat 5 tagcata 5' FAM probe FAM-caggtggaacctcat 6 caggagatgc-BBQ Note: FAM and BBQ respectively represent fluorescein and BlackBerry .RTM. Quencher.

Results:

[0058] FIG. 3 illustrates RNA quantification (expressed as log RNA copy number/mL) of E gene (upper panel) and RdRp gene (lower panel) of SARS-CoV-2 in the infected LLC-MK2 cells pretreated with pioglitazone. As shown in FIG. 3, as compared to the control group, pioglitazone leads to significant reduction in RNA expression of each of E and RdRp genes of SARS-CoV-2 in the infected LLC-MK2 cells, indicating that pioglitazone can reduce the viral gene expression and thereby inhibit the viral replication in the host cells.

B. Immunofluorescence Microscopy:

[0059] LLC-MK2 cells were pretreated with 20 .mu.M of pioglitazone for 1 hour, and then were infected with SARS-CoV-2 at m.o.i. of 0.01 according to the procedures as described in the preceding section, entitled "1. Virus infection," of the General Experimental Procedures. In comparison, SARS-CoV-2-infected LLC-MK2 cells pretreated with 0.08% DMSO served as an infection control group, and mock-infected LLC-MK2 cells pretreated with pioglitazone served as a normal control group.

[0060] At 4 d.p.i., the cells were washed with PBS and fixed with 4% formaldehyde for 10 minutes at room temperature. Then, the cells were permeabilized and subjected to immunostaining for detection of SARS-CoV-2 spike (S2 subunit) and nucleocapsid proteins using the primary and secondary antibodies shown in Table 3 below, and the nucleus of the cells was stained with DAPI (Manufacturer: Invitrogen; Catalog no.: D1306). Thereafter, the stained cells were examined using a fluorescence microscope (Manufacturer: Olympus Corporation; Model No.: IX71).

TABLE-US-00003 TABLE 3 Proteins Primary antibody Secondary antibody SARS-CoV-2 Mouse anti-SARS-CoV-2 Alexa Fluor 488 spike spike monoclonal goat anti-mouse IgG antibody (Cat. No. A-11001, (Cat. No. GTX632604, Invitrogen, GeneTex, Irvine, CA) Waltham, MA) SARS-CoV-2 Rabbit anti-SARS-CoV-2 Alexa Fluor 594 nucleocapsid nucleocapsid goat anti-rabbit IgG polyclonal antibody (Cat. No. A-11012, (Cat. No. GTX135361, Invitrogen, GeneTex, Irvine, CA) Waltham, MA)

Results:

[0061] FIG. 4 shows fluorescence microscopy images of expression of the spike and nucleocapside proteins of SARS-CoV-2 in the LLC-MK2 cells pretreated with pioglitazone. It can be seen from FIG. 4 that, as compared to the mock-infected LLC-MK2 cells, the spike and nucleocapside proteins are clearly expressed in the infection control group, indicating that SARS-CoV-2 viruses have been replicated in the infected cells. However, such viral replication is significantly reduced in the cells pretreated with pioglitazone, suggesting that pioglitazone exerts an inhibitory effect against SARS-CoV-2 infection.

C. Viral Plaque Reduction Assay:

[0062] Vero E6 cells were seeded at 5.times.10' cells per well into 6-well plates containing 10% FBS MEM, and were cultured in an incubator (37.degree. C. and 5% CO.sub.2) for 24 hours. Next, the Vero E6 cells were pretreated with 20 .mu.M of pioglitazone for 1 hour, and then were infected with SARS-CoV-2 at 100 P.F.U., according to the procedures as described in the preceding section, entitled "1. Virus infection," of the General Experimental Procedures. After that, the SARS-CoV-2-infected Vero E6 cells were washed with PBS, and then 3 mL of an agarose overlay medium (0.3% agarose in MEM containing 2% FBS) containing 20 .mu.M of pioglitazone was added to each well. After the pioglitazone-containing agarose overlay medium had solidified, the plates were placed in a 37.degree. C. incubator. Subsequently, the SARS-CoV-2 viruses in the infected Vero E6 cells were harvested at 3 d.p.i. for determination of virus titers. The cells in each well were fixed with 2 mL of a 10% formaldehyde solution at room temperature for 2 hours. Next, the agarose overlay in each well was removed, and then the fixed cells in each well were stained with 0.5% crystal violet (Manufacturer: Sigma Aldrich) for 2 min. After rinsing the stained cells with water, distribution of the viral plaques in each well was analyzed by visual observation. In comparison, SARS-CoV-2-infected Vero E6 cells cultured in a pioglitazone-free agarose overlay medium (0.3% agarose in MEM containing 2% FBS), which served as a control group, were subjected to the same analysis.

Results:

[0063] FIG. 5 shows the viral plaques of the SARS-CoV-2 in the Vero E6 cells treated with pioglitazone. As shown in FIG. 5, the size and number of the viral plaques of the SARS-CoV-2 were reduced in the pioglitazone-treated Vero E6 cells as compared to the control group.

[0064] Taken together, the above results demonstrate that pioglitazone can effectively inhibit replication of coronavirus, such as SARS-CoV-2.

[0065] In the description above, for the purposes of explanation, numerous specific details have been set forth in order to provide a thorough understanding of the embodiments. It will be apparent, however, to one skilled in the art, that one or more other embodiments may be practiced without some of these specific details. It should also be appreciated that reference throughout this specification to "one embodiment," "an embodiment," an embodiment with an indication of an ordinal number and so forth means that a particular feature, structure, or characteristic may be included in the practice of the disclosure. It should be further appreciated that in the description, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure and aiding in the understanding of various inventive aspects, and that one or more features or specific details from one embodiment may be practiced together with one or more features or specific details from another embodiment, where appropriate, in the practice of the disclosure.

[0066] While the disclosure has been described in connection with what are considered the exemplary embodiments, it is understood that this disclosure is not limited to the disclosed embodiments but is intended to cover various arrangements included within the spirit and scope of the broadest interpretation so as to encompass all such modifications and equivalent arrangements.

Sequence CWU 1

1

6126DNAArtificial SequenceForward primer for E gene of SARS-CoV-2 1acaggtacgt taatagttaa tagcgt 26222DNAArtificial SequenceReverse primer for E gene of SARS-CoV-2 2atattgcagc agtacgcaca ca 22326DNAArtificial Sequence5'-end FAM probe for E gene of SARS-CoV-2 3acactagcca tccttactgc gcttcg 26422DNAArtificial SequenceForward primer for RdRp gene of SARS-CoV-2 4gtgaratggt catgtgtggc gg 22526DNAArtificial SequenceReverse primer for RdRp gene of SARS-CoV-2 5caratgttaa asacactatt agcata 26625DNAArtificial Sequence5'-end FAM probe for RdRp gene of SARS-CoV-2 6caggtggaac ctcatcagga gatgc 25

Claims

1. A method for inhibiting coronavirus infection, comprising administering to a subject in need thereof an effective amount of pioglitazone or a pharmaceutically acceptable salt thereof.

2. The method as claimed in claim 1, wherein the coronavirus infection is caused by a coronavirus selected from the group consisting of a member of Alphacoronavirus genus, a member of Betacorovirus genus, a member of Gammacoronavirus genus, a member of Deltacoronavirus genus, and combinations thereof.

3. The method as claimed in claim 2, wherein the coronavirus is selected from the group consisting of bat coronavirus CDPHE 15, bat coronavirus HKU10, Rhinolopus ferrumequinum alphacoronavirus HuB-2013, human coronavirus 229E (HCoV-229E), Lucheng Rn rat coronavirus, mink coronavirus 1, Miniopterus bat coronavirus 1, Miniopterus bat coronavirus HKU8, Myotis ricketti alphacoronavirus Sax-2011, Nyctalus velutinus alphacoronavirus SC-2013, Pipistrellus kuhlii coronavirus 3398, porcine epidemic diarrhea virus, Scotophilus bat coronavirus 512, Rhinolophus bat coronavirus HKU2, human coronavirus NL63, NL63-related bat coronavirus strain BtKYNL63-9b, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, Alphacoronavirus 1, bovine coronavirus, human coronavirus OC43 (HCoV-OC43), China rattus coronavirus HKU24, human coronavirus HKU1, murine coronavirus, Myodes coronavirus 2JL14, bat Hp-betacoronavirus Zhejiang 2013, Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus, Pipistrellus bat coronavirus HKU5, Tylonycteris bat coronavirus HKU4, Eidolon bat coronavirus C704, Rousettus bat coronavirus GCCDC1, Rousettus bat coronavirus HKU9, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), bat SARS-like coronavirus WIV1, and combinations thereof.

4. The method as claimed in claim 3, wherein the coronavirus is HCoV-229E.

5. The method as claimed in claim 3, wherein the coronavirus is HCoV-OC43.

6. The method as claimed in claim 3, wherein the coronavirus is SARS-CoV-2.

7. The method as claimed in claim 1, wherein the pioglitazone or the pharmaceutically acceptable salt thereof is in a dosage form for oral administration.

8. A method for inhibiting coronavirus replication, comprising contacting a coronavirus with pioglitazone or a pharmaceutically acceptable salt thereof.

9. The method as claimed in claim 8, wherein the coronavirus is selected from the group consisting of a member of Alphacoronavirus genus, a member of Betacorovirus genus, a member of Gammacoronavirus genus, a member of Deltacoronavirus genus, and combinations thereof.

10. The method as claimed in claim 9, wherein the coronavirus is selected from the group consisting of bat coronavirus CDPHE 15, bat coronavirus HKU10, Rhinolopus ferrumequinum alphacoronavirus HuB-2013, human coronavirus 229E (HCoV-229E), Lucheng Rn rat coronavirus, mink coronavirus 1, Miniopterus bat coronavirus 1, Miniopterus bat coronavirus HKU8, Myotis ricketti alphacoronavirus Sax-2011, Nyctalus velutinus alphacoronavirus SC-2013, Pipistrellus kuhlii coronavirus 3398, porcine epidemic diarrhea virus, Scotophilus bat coronavirus 512, Rhinolophus bat coronavirus HKU2, human coronavirus NL63, NL63-related bat coronavirus strain BtKYNL63-9b, Sorex araneus coronavirus T14, Suncus murinus coronavirus X74, Alphacoronavirus 1, bovine coronavirus, human coronavirus OC43 (HCoV-OC43), China Rattus coronavirus HKU24, human coronavirus HKU1, murine coronavirus, Myodes coronavirus 2JL14, bat Hp-betacoronavirus Zhejiang 2013, Hedgehog coronavirus 1, Middle East respiratory syndrome-related coronavirus, Pipistrellus bat coronavirus HKU5, Tylonycteris bat coronavirus HKU4, Eidolon bat coronavirus C704, Rousettus bat coronavirus GCCDC1, Rousettus bat coronavirus HKU9, severe acute respiratory syndrome coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), bat SARS-like coronavirus WIV1, and combinations thereof.

11. The method as claimed in claim 10, wherein the coronavirus is HCoV-229E.

12. The method as claimed in claim 10, wherein the coronavirus is HCoV-OC43.

13. The method as claimed in claim 10, wherein the coronavirus is SARS-CoV-2.